Q3 2022 Results

Company overview Financial review 2022 priorities Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials Cardiovascular Immunology Neuroscience Oncology remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor References Indication NCT05147220 REMODEL-1 (CLOU064C12301) Multiple sclerosis Indication NCT05156281 REMODEL-2 (CLOU064C12302) Multiple sclerosis Phase Phase 3 Phase Phase 3 Patients 800 Patients 800 Primary Outcome Measures Annualized relapse rate (ARR) of confirmed relapses [Core Part]. ARR is the average number of confirmed MS relapses in a year Primary Outcome Measures Annualized relapse rate (ARR) of confirmed relapses Arms Intervention Arm 1: Experimental; Remibrutinib - Core (Remibrutinib tablet and matching placebo of teriflunomide capsule) Arms Arm 1: Experimental; Remibrutinib - Core Intervention Arm 2: Active Comparator; Teriflunomide - Core (Teriflunomide capsule and matching placebo remibrutinib tablet) Arm 3: Experimental; Remibrutinib - Extension (Participants on remibrutinib in Core will continue on remibrutinib tablet) Arm 4: Experimental; Remibrutinib - Extension (on teriflunomide in Core) (Participants on teriflunomide in Core will switch to remibrutinib tablet) Patients with relapsing Multiple Sclerosis Estimated primary completion 2026 Target Patients Read-out Milestone(s) Publication TBD 63 Investor Relations | Q3 2022 Results Abbreviations Other Remibrutinib tablet and matching placebo of teriflunomide capsule Arm 2: Active Comparator; Teriflunomide - Core Teriflunomide capsule and matching placebo remibrutinib tablet Arm 3: Experimental: Remibrutinib - Extension Participants on remibrutinib in Core will continue on remibrutinib tablet Arm 4: Experimental: Remibrutinib - Extension (on teriflunomide in Core) Participants on teriflunomide in Core will switch to remibrutinib tablet Patients with relapsing Multiple Sclerosis Estimated primary completion 2026 Target Patients Read-out Milestone(s) Publication TBD 1 NOVARTIS | Reimagining Medicine

View entire presentation